These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37128470)

  • 1. Impacts of Eligibility Criteria on Trial Participants' Age in Alzheimer's Disease Clinical Trials.
    Chen A; Li Q; He X; Jaffee MS; Hogan WR; Wang F; Guo Y; Bian J
    AMIA Annu Symp Proc; 2022; 2022():368-376. PubMed ID: 37128470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of eligibility criteria in Alzheimer's and related dementias clinical trials.
    Mitchell AK; Ehrenkranz R; Franzen S; Han SH; Shakur M; McGowan M; Massett HA
    Sci Rep; 2024 Jul; 14(1):15036. PubMed ID: 38951633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XGBoost-SHAP-based interpretable diagnostic framework for alzheimer's disease.
    Yi F; Yang H; Chen D; Qin Y; Han H; Cui J; Bai W; Ma Y; Zhang R; Yu H
    BMC Med Inform Decis Mak; 2023 Jul; 23(1):137. PubMed ID: 37491248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer's Disease Trials.
    Li Q; Guo Y; He Z; Zhang H; George TJ; Bian J
    AMIA Annu Symp Proc; 2020; 2020():717-726. PubMed ID: 33936446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning enabled subgroup analysis with real-world data to inform clinical trial eligibility criteria design.
    Xu J; Zhang H; Zhang H; Bian J; Wang F
    Sci Rep; 2023 Jan; 13(1):613. PubMed ID: 36635438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Effect of Eligibility Criteria on AD Severity and Severe Adverse Event in Eligible Patients.
    Chen A; Li Q; Shenkman E; Wu Y; Guo Y; Bian J
    Proc (IEEE Int Conf Healthc Inform); 2023 Jun; 2023():756-759. PubMed ID: 39070248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Alzheimer's Disease with Interpretable Machine Learning.
    Jia M; Wu Y; Xiang C; Fang Y
    Dement Geriatr Cogn Disord; 2023; 52(4):249-257. PubMed ID: 37482057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial.
    Raman R; Quiroz YT; Langford O; Choi J; Ritchie M; Baumgartner M; Rentz D; Aggarwal NT; Aisen P; Sperling R; Grill JD
    JAMA Netw Open; 2021 Jul; 4(7):e2114364. PubMed ID: 34228129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data analysis with Shapley values for automatic subject selection in Alzheimer's disease data sets using interpretable machine learning.
    Bloch L; Friedrich CM;
    Alzheimers Res Ther; 2021 Sep; 13(1):155. PubMed ID: 34526114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning application for classification of Alzheimer's disease stages using
    Park SW; Yeo NY; Lee J; Lee SH; Byun J; Park DY; Yum S; Kim JK; Byeon G; Kim Y; Jang JW;
    Biomed Eng Online; 2023 Apr; 22(1):40. PubMed ID: 37120537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
    Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
    J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning analyses identify multi-modal frailty factors that selectively discriminate four cohorts in the Alzheimer's disease spectrum: a COMPASS-ND study.
    Bohn L; Drouin SM; McFall GP; Rolfson DB; Andrew MK; Dixon RA
    BMC Geriatr; 2023 Dec; 23(1):837. PubMed ID: 38082372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automatic trial eligibility surveillance based on unstructured clinical data.
    Meystre SM; Heider PM; Kim Y; Aruch DB; Britten CD
    Int J Med Inform; 2019 Sep; 129():13-19. PubMed ID: 31445247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria.
    Franzen S; Smith JE; van den Berg E; Rivera Mindt M; van Bruchem-Visser RL; Abner EL; Schneider LS; Prins ND; Babulal GM; Papma JM
    Alzheimers Dement; 2022 Apr; 18(4):810-823. PubMed ID: 34590409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.
    Gerber DE; Singh H; Larkins E; Ferris A; Forde PM; Selig W; Basu Roy U
    JAMA Oncol; 2022 Sep; 8(9):1333-1339. PubMed ID: 35925576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eligibility of Alzheimer's disease clinic patients for clinical trials.
    Schneider LS; Olin JT; Lyness SA; Chui HC
    J Am Geriatr Soc; 1997 Aug; 45(8):923-8. PubMed ID: 9256842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
    Grill JD; Flournoy C; Dhadda S; Ernstrom K; Sperling R; Molina-Henry D; Tranotti K; Harris R; Kanekiyo M; Gee M; Irizarry M; Kramer L; Aisen P; Raman R
    Ann Neurol; 2024 Feb; 95(2):288-298. PubMed ID: 37830926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Blood-Based Glycolysis Gene Associated with Alzheimer's Disease by Integrated Bioinformatics Analysis.
    Wang F; Xu CS; Chen WH; Duan SW; Xu SJ; Dai JJ; Wang QW
    J Alzheimers Dis; 2021; 83(1):163-178. PubMed ID: 34308907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.